SCHEMBL3175386

SCHEMBL3175386

Cc1ccc(-n2nc(C(C)(C)C)cc2N(OS(C)(=O)=O)C(=O)Nc2ccc(N3CCN(C(=O)CC4CCCC4)CC3)nc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
CNR2 P34972 2/20 0.38
NAMPT P43490 2/20 0.36
FGFR3 P22607 1/20 0.36
PDE7A Q13946 2/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPK14 Q16539 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
CYP2C19 P33261 2/20 0.34
MEN1 O00255 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPK13 O15264 3/20 0.34
MAPK9 P45984 1/20 0.34
MAPK12 P53778 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3390558 0.89 MAPK13 (0.40) KDM4EALDH1A1HSD17B10PDE7ARAB9A
SCHEMBL3390571 0.87 PANK3 (0.36) KDM4EHSD17B10PDE7ARAB9AL3MBTL1
SCHEMBL3389956 0.86 RAB9A (0.36) KDM4EALDH1A1RAB9AL3MBTL1MAPK14
SCHEMBL3390498 0.85 RAB9A (0.36) ALDH1A1PDE7ARAB9AL3MBTL1MAPK14
SCHEMBL3175376 0.84 MAPK14 (0.53) MAPK14CYP2C9MAPK13MAPK9MAPK12
SCHEMBL3174639 0.82 MAPK14 (0.56) MAPK14CYP2C9MAPK13MAPK9MAPK12
SCHEMBL4602779 0.81 MAPK13 (0.45) NAMPTMAPK14MEN1CYP2C9KMT2A
SCHEMBL4602880 0.79 MAPK14 (0.43) ALDH1A1MAPK14CYP2C19MEN1CYP2C9
SCHEMBL3390651 0.78 SMO (0.37) KDM4EALDH1A1MAPK14MAPK13MAPK9
SCHEMBL4602876 0.78 MAPK14 (0.42) KDM4EALDH1A1NAMPTMAPK14CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943243-B1 KINASE INHIBITORS LILLY CO ELI (US) 2010-12-29 EP disclosed
US-7652015-B2 Suppression cytokines , tumor necrosis factor ELI LILLY AND COMPANY (US) 2010-01-26 US disclosed
US-20080269244-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269244-A1 Kinase Inhibitors MAP3K1, MAP3K20, MAP3K19 KDM4E 744/4885ALDH1A1 2938/4885HSD17B10 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.